Which of the following NSAIDs is a COX-2 inhibitor?

Celecoxib is a selective COX-2 inhibitor, making it unique among nonsteroidal anti-inflammatory drugs (NSAIDs). COX-2 inhibitors are designed to reduce inflammation and pain with a lower risk of gastrointestinal side effects commonly associated with traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes.

The COX-2 enzyme is primarily responsible for the inflammatory process and pain perception, while COX-1 plays a protective role in the stomach lining and in platelet function. By selectively targeting COX-2, celecoxib can provide anti-inflammatory benefits without significantly impacting COX-1 activity, thus minimizing gastrointestinal complications.

In comparison, the other options listed, such as Diclofenac, Meloxicam, and Sulindac, are not selective COX-2 inhibitors. These drugs inhibit both COX-1 and COX-2, which can lead to increased risk of gastrointestinal side effects, such as ulcers and bleeding. This distinction emphasizes the therapeutic advantage of celecoxib in specific patient populations, particularly those at risk for gastric complications.